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ABSTRACT
Objective: To compare the rate of progression of
diabetic chronic kidney disease in different ethnic groups.
Design: Prospective longitudinal observational study.
Participants: All new patients attending a tertiary renal
unit in east London with diabetic chronic kidney disease
between 2000 and 2007 and followed up till 2009 were
included. Patients presenting with acute end-stage kidney
failure were excluded.
Main outcome measures: The primary outcome was
annual decline in the estimated glomerular filtration rate
(eGFR) in different ethnic groups. Secondary end points
were the number of patients developing end-stage kidney
failure and total mortality during the study period.
Results: 329 patients (age 60±11.9 years, 208 men)
were studied comprising 149 south Asian, 105 White
and 75 Black patients. Mean follow-up was 6.0±2.3, 5.0
±2.7 and 5.6±2.4 years for White, Black and south Asian
patients, respectively. South Asian patients were younger
and had a higher baseline eGFR, but both systolic and
diastolic blood pressures were higher in Black patients
(p<0.05). Baseline proteinuria was highest for the south
Asian group followed by the White and Black groups.
Adjusted linear regression analysis showed that an
annual decline in eGFR was not significantly different
between the three groups. The numbers of patients
developing end-stage kidney failure and total mortality
were also not significantly different between the three
groups. ACE or angiotensin receptor blockers use, and
glycated haemoglobin were similar at baseline and
throughout the study period.
Conclusions:We conclude that ethnicity is not an
independent factor in the rate of progression renal failure
in patients with diabetic chronic kidney disease.
INTRODUCTION
Diabetic chronic kidney disease (DCKD) is
one of the leading causes of end-stage kidney
failure (ESKF), accounting for 21% of all
such cases in the UK.1 Suboptimal glycaemic
and blood pressure (BP) control, develop-
ment of albuminuria and family history are
important risk factors for the development of
CKD in diabetic patients.
There is a higher prevalence of diabetes
mellitus (DM) in Black and south Asian
populations. The prevalence of diabetes
among Black Caribbean and Indian men has
been reported to be approximately 10%
compared with 4.3% in Whites.2 A recent
study was conducted in one of the most eth-
nically diverse cities in the UK where the
incidence of renal replacement therapy
(RRT) for south Asian and Black groups was
reported to be, respectively, 1.88 and 2.16
times greater than for White patients.3
Therefore, it is not surprising that a higher
proportion of patients on RRT comes from
ethnic minority groups compared to the UK
White population (17.8% vs 11%).4
Mortality is also 3.5 times higher in south
Asian and Black populations with diabetes
compared to Whites in England and Wales.5
ARTICLE SUMMARY
Article focus
▪ The aim of the study is to compare the rate of
progression of diabetic chronic kidney disease
(CKD) in different ethnic groups.
▪ To examine the number of patients developing
end-stage kidney failure (ESKF) and total mortal-
ity by ethnicity.
Key messages
▪ This study demonstrates that there is no signifi-
cant interaction between ethnicity and the rate of
progression of CKD in patients with diabetes
mellitus.
▪ The prevalence of renal replacement therapy,
indicating ESKF, and mortality was also similar
between the different ethnic groups.
Strengths and limitations of this study
▪ The strengths of this study include the large
number of cases and the prolonged period of
follow-up.
▪ Weaknesses include combining ethnic sub-
groups into three broad categories, which may
mask differences in treatment or progression.
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The higher incidence of ESKF in south Asian and Black
populations may be related to higher incidence and
poorer control of diabetes and hypertension. However, it
may also be related to faster progression of DCKD in
ethnic minority populations. There are conﬂicting
reports on progression of DCKD in these population
subgroups. Higher rates of kidney function decline have
been reported in some studies while others have failed
to show this trend.6–9
Most studies comparing progression of DCKD in eth-
nically diverse populations have either been small or
had a short duration of follow-up. The renal clinic at the
Royal London Hospital in east London serves an ethnic-
ally diverse population in a large urban centre. The aim
of our study is ﬁrst to determine whether the rate of
kidney function decline differs by ethnic group after
controlling for demographic characteristics and clinical
parameters known to be associated with progression of
CKD, and second, to examine the number of patients
developing ESKF and total mortality by ethnicity.
MATERIALS AND METHODS
Population
The study was conducted at the Royal London Hospital,
which serves as a tertiary referral centre for three
primary care trusts in east London: Newham, Tower
Hamlets, and City and Hackney, with a combined
general practitioner (GP) registered population of
885 625 at the end of 2011. The prevalence of CKD
among patients with diabetes, based on a local study, is
18%.10
All adult patients above the age of 18 years with biopsy
proven or clinical diagnosis of DCKD (where all second-
ary causes were excluded) attending our kidney out-
patient clinic were included in the study. Any other
diagnosis of CKD, and those presenting acutely with
ESKF were excluded from the study.
Ethnicity was self-assigned by the patient. Patients were
grouped according to the ethnic categories of the 2001
census. For the purpose of this study, patients of Indian,
Bangladeshi and Pakistani ethnicity were analysed
together as the south Asian subgroup. Patients of
African and Caribbean ethnicity were grouped together
to form the Black subgroup, though we recognise that
these groupings may conceal underlying heterogeneity.
Participants were recruited to the study from 2000 until
2007 and followed up prospectively until 2009. Patients
left the study if they moved away, died, were started on
dialysis or transplanted. The follow-up for the remaining
patients was censored at the end of 2009.
Clinical data collection
Data were captured electronically using an inhouse
renal information technology programme (File maker
pro) at every clinic visit. This included BP measured in
the sitting position using cuffs appropriate for individual
and all clinical events and changes in medication.
Ethical approval was sought, but not required, due to
the observational nature of the study utilising routinely
collected, anonymised patient data.
Baseline variables were collected at the ﬁrst clinic visit
and subsequently updated at every clinic visit. The study
variables were deﬁned as follows: ischaemic heart
disease (IHD) included patients who had a documented
history of angina, myocardial infarction or cardiac revas-
cularisation. Diabetic retinopathy included patients who
had been diagnosed with the condition by the diabetic
ophthalmology clinic. Peripheral vascular disease (PVD)
included patients with a history of intermittent claudica-
tion or documented vascular disease on an angiogram,
and cerebrovascular disease (CVD) included patients
with a history of transient or persistent vascular neuro-
logical deﬁcit.
Estimated glomerular ﬁltration rate (eGFR) was calcu-
lated based on the four-variable Modiﬁcation of Diet in
Renal Disease (MDRD) equation which includes a cor-
rection for Black ethnicity. Serum creatine was measured
using a Roche Modular Platform automated analyser.
Proteinuria was determined using the protein creatine
ratio, PCR (Roche Modular Platform automated ana-
lyser). PCR was only calculated for patients who had
positive proteins on a urine dipstick, and thus indivi-
duals with no PCR data were considered to have a value
less than 15. This was based on a separate unit practice
development observation on all dipstick negative urine
samples in diabetic patients who when analysed had
PCR<15 (personal communication). Glycated haemoglo-
bin (HbA1c) was used to assess glycaemic control
(BioRad Turbo 2 automated analyser). Data on systolic
BP (SBP) and diastolic BP (DBP), HbA1c, proteinuria
and eGFR were collected every 6 months.
Data coding
Data were cleaned, coded and analysed using Stata 10.
Baseline variables were created for: average eGFR, SBP,
DBP, PCR and HbA1c value. PCR was considered both
as a linear variable and a binary variable (presence or
absence of proteinuria at baseline deﬁned as PCR>15).
Medications were coded a constant variable (ever
present vs never present) for ACE inhibitors (ACEi),
angiotensin receptor blockers (ARBs) or dual blockade.
Descriptive analysis
Bivariate statistics outlining the population breakdown
by ethnicity were conducted. Analysis of variance
(ANOVA) was used to examine ethnic differences in the
means of continuous variables, while χ2 tests were used
to examine differences in ethnic differences for categor-
ical variables.
Statistical methods
Unadjusted and adjusted linear regression models were
used to determine whether the annual change in eGFR
differed by ethnic group. For this analysis, the eGFR
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values collected every 6 months were collapsed together
to form annual averages.
To investigate whether the annual decline in eGFR
was modiﬁed by ethnicity, an interaction term between
years of follow-up and ethnic group was utilised. The
addition of an interaction term between ethnicity and
‘year squared’ to the linear model already containing an
interaction between ethnicity and year was shown to be
non-signiﬁcant, thus suggesting to us to proceed with a
model examining linear annual change in eGFR.
The adjusted analysis controlled for age at baseline,
gender, presence or absence of vascular disease
(deﬁned as any prior diagnosis of CVD, PVD or IHD),
presence or absence of drug treatment (deﬁned as any
prior prescription of ACEi, ARBs or dual blockade),
presence or absence of proteinuria at baseline (deﬁned
as a baseline PCR value greater than 15) and baseline
eGFR. In addition, the analysis included interaction
terms to examine the effect of BP and HbA1c being con-
trolled to target in each year of follow-up. The BP target
was set at ≤130/80 mm Hg and the HbA1c target was
≤7.5%.
ANOVA was used to examine ethnic differences in the
distribution of continuous variables, while χ2 tests were
used for categorical variables. Finally, survival analysis
using Cox regression was used to estimate ethnic differ-
ences in the risk of death adjusting for age and gender.
RESULTS
Population
Of a total of 356 eligible patients, a total of 329 patients
with more than 6 years follow-up were included.
Twenty-seven patients were excluded because 10 pre-
sented with ESKF and 17 patients had no ethnicity data.
Less than 10% of the patients had missing data, which
was attributed to missing clinics, and less than 5% were
lost to follow-up due to death or relocation. The base-
line characteristics are shown in table 1.
The south Asian group was the youngest, with a
shorter duration of diabetes and lower baseline BP in
comparison to Whites. The Black group has the shortest
duration of diabetes but higher baseline SBP and DBP.
Baseline eGFR was highest for the south Asian group
and lowest for the White group. Mean HbA1c did not
differ between ethnic groups, while baseline proteinuria
was highest for the south Asian group followed by the
White and Black groups. Prevalence of IHD was highest
Table 1 Baseline characteristics of study participants by ethnic group
Characteristic White Black South Asian p Value
N 105 75 149
Baseline measures*
Mean age (years) 61.3±12.6 62.4±11.3 57.8±11.4 0.005
Male (%) 61.5 66.2 65.8 0.741
T2DM (%) 85 100 98 <0.001
Duration of diabetes (years) 18.3±11.6 13.4±7.1 14.0±12.9 0.013
Duration of follow-up (years) 6.0±2.3 5.0±2.7 5.6±2.4 0.05
Diabetic retinopathy (%) 84 81 76 0.110
Mean eGFR (ml/min/1.732) 38.1±19 39.0±21 44.3±21 0.039
Mean systolic BP (mm Hg) 146.6±26 158.3±23 136.6±24 <0.001
Systolic BP >130 mm Hg (%) 78.1 86.7 61.7 <0.001
Mean diastolic BP (mm Hg) 76±11 83±15 75±11 0.002
Diastolic BP >80 (%) 46.7 53.3 37.6 0.066
Mean HbA1c (%) 8.5±1.8 8.8±2.2 8.7±1.9 0.445
HbA1c>7.5% (%) 67.6 69.3 71.1 0.833
PCR>15 mg/mmol (%) 58.2 47.5 64.4 <0.001
Constant measures
IHD (%) 28.6 21.3 38.9 0.020
PVD (%) 15.2 10.7 12.1 0.626
CVD (%) 10.5 8.0 10.7 0.799
Statin use (%) 83.8 80.0 80.4 0.742
ACE use (%) 72.4 70.7 73.7 0.894
ARB use (%) 34.3 40.0 41.2 0.519
Dual blockade (%) 14.3 17.3 20.1 0.483
Current smoker (%) 18.6 13.6 13.1 0.609
Outcome measures
End-stage kidney failure (%) 32.4 44.0 38.9 0.272
Death (%) 10.5 12.0 8.1 0.612
*Mean values±SD.
ARB, angiotensin receptor blocker; BP, blood pressure; CVD, cerebrovascular disease; eGFR, estimated glomerular filtration rate; HbA1c,
glycated haemoglobin; IHD, ischaemic heart disease; PCR, protein creatine ratio; PVD, peripheral vascular disease; T2DM, type 2 diabetes
mellitus.
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for the south Asian patients. Prevalence of other
comorbidities, smoking and drug prescription was not
signiﬁcantly different between the three groups.
Primary end point (annual decline in eGFR)
The overall annual decrease in eGFR was −1.69 in the
total population. In the unadjusted linear regression ana-
lysis, the annual decline in eGFR in the White, Black and
south Asian groups was −1.78, −2.02 and −1.51, respect-
ively. There was no signiﬁcant difference in the rate of
decline in eGFR between the three groups (table 2).
Furthermore, the adjusted linear regression analysis
indicated no signiﬁcant differences in the annual change
in eGFR between the ethnic groups over the entire study
period. However, the analysis showed that control of BP,
gender and degree of renal impairment at baseline were
signiﬁcant predictors of progression (table 3).
Secondary end points
By the end of the observation period, 125 individuals
had developed ESKF, 32 individuals had died and 172
individuals were censored. The crude proportions of
ESKF were 32%, 44% and 38% in the White, Black and
south Asian groups, respectively, and were not statistically
different (p=0.272). After adjusting for age and gender,
the survival analysis indicated no signiﬁcant difference
by ethnicity in the risk of death (table 4).
DISCUSSION
In this single centre longitudinal prospective observa-
tional study of patients with DCKD, the average annual
Table 2 Unadjusted regression for annual change in estimated glomerular filtration rate (n=329)
Annual change (ml/min/1.732) 95% CI p Value
Predictor variables
Overall pop −1.69 −1.84 to −1.53 <0.001
Slope in White −1.71 −1.98 to −1.44 <0.001
Coefficients for ethnicity interaction (additional decline in ml/min/1.732/year)
Additional decline in Black population −0.31 −0.75 to 0.13 0.161
Additional decline in south Asian population 0.19 −0.16 to 0.55 0.285
The annual decline in White patients is −1.71 ml/min/1.732.
The annual decline in Black patients is −2.02 ml/min/1.732.
The annual decline in south Asian patients is −1.51 ml/min/1.732.
Table 3 Adjusted linear regression for annual change in eGFR (n=329)
Annual change (ml/min/1.732) 95% CI p Value
Predictor variables
Years of follow-up (slope in reference pop) −1.93 −2.31 to −1.56 <0.001
Coefficients for ethnicity interaction (additional decline in ml/min/1.732 per year)
Additional decline in Black population −0.19 −0.68 to 0.30 0.438
Additional decline in south Asian population 0.08 −0.31 to 0.48 0.676
Time-varying variables
BP≤ 130/80 mm Hg × time in years 0.62 0.27 to 0.98 <0.001
HbA1c≤ 7.5%×time in years 0.03 −0.33 to 0.39 0.883
Constant variables
Ethnicity (White is reference category)
Black ethnicity −1.67 −4.97 to 1.64 0.322
South Asian ethnicity −0.51 −3.25 to 2.23 0.716
Age 0.03 −0.06 to 0.13 0.466
Gender (female is reference category) −2.64 −4.87 to −0.40 0.021
SBP target at baseline −2.31 −3.89 to −0.73 0.004
HbA1c value at baseline −0.66 −2.37 to 1.06 0.454
Vascular disease ever (PVD, CVD, IHD) −1.44 −3.66 to 0.79 0.206
Drug treatment ever (ACE, ARB, dual block) 0.02 −4.46 to 4.50 0.993
Proteinuria at baseline (PCR>15) 0.173 −1.99 to 2.33 0.875
Baseline eGFR 1.05 0.99 to 1.11 <0.001
Constant −3.18 −11.26 to 4.89 0.440
The annual decline in the reference population (White) is −1.93 ml/min.
The annual decline in Black patients is −2.12 ml/min.
The annual decline in south Asian patients is −1.85 ml/min.
ARB, angiotensin receptor blocker; BP, blood pressure; CVD, cerebrovascular disease; eGFR, estimated glomerular filtration rate; HbA1c,
glycated haemoglobin; IHD, ischaemic heart disease; PCR, protein creatine ratio; PVD, peripheral vascular disease; SBP, systolic blood
pressure
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decrease in eGFR in the whole population was
−1.69 ml/min/1.732. No signiﬁcant differences in the
rate of progression by ethnic group were evidenced. To
date, this is the largest study of its kind in the literature.
Burden et al7 have reported previously that south
Asians with diabetes are 13 times more likely to develop
ESKF than their White counterparts, suggesting a faster
progression of CKD. A study carried out in the UK,
which supports this hypothesis, found that the propor-
tion of patients doubling their creatine was signiﬁcantly
higher in south Asians compared to Whites.8 However,
this study had signiﬁcantly fewer patients than our study
and their patients had early CKD at baseline compared
with our population who had moderately severe renal
impairment at presentation, which was an independent
predictor of progression of renal failure. In contrast,
another small study (39 patients) in the UK by Koppiker
et al.9 has suggested no difference in the rate of progres-
sion between Whites and south Asians.9 However, com-
plete data were available for only 36 patients. Similarly, a
study in the USA has also reported no signiﬁcant differ-
ences in progression of diabetic kidney disease between
the Black and White populations with equivalent dia-
betic control.6 Our results are broadly in agreement with
these studies by demonstrating a lack of interaction
between ethnicity and the rate of decline in kidney func-
tion, though Black patients had a modest additional
unadjusted annual decline of 0.31 ml/min/1.732.
BP and glycaemic control are important risk factors for
progression of DCKD. Generally BP control is more difﬁ-
cult to achieve among Black populations and may con-
tribute towards a faster rate of kidney function decline.
One study showed that there was no signiﬁcant difference
in the rate of kidney function decline after adjusting for
the effects of glycaemic control in Black populations
compared with Whites, while others have shown signiﬁ-
cant differences despite equivalent BP and glycaemic
control. A difference in the use of antihypertensive medi-
cation including renin angiotensin blocking medication
(RAAS) has also been suggested.9 11 12 In this study, there
was no signiﬁcant difference in glycaemic control or the
use of RAAS in the three groups. However, Black patients
had a signiﬁcantly higher baseline SBP, DBP and above
target BP. In our previous study, we observed a higher
prevalence of BP>150/90 in Blacks in a community-based
cohort with mild CKD,10 a result which is conﬁrmed by
this study in a hospital-based cohort of patients with
DCKD. Although, there was no signiﬁcant difference in
the decline of kidney function between ethnic groups in
this study, the adjusted analysis showed that the lack of
control of BP below the target of 130/80 mm Hg was
independently associated with a rapid decline of eGFR
underscoring the importance of optimal BP manage-
ment as a key modiﬁable risk factor. Moreover, as
expected, gender and severity of renal impairment were
the other signiﬁcant predictors of progression of diabetic
kidney disease (table 3).
There was no signiﬁcant difference in total mortality
(table 4) and prevalence of ESKF between the different
ethnic groups; however, the study was not powered to
address this question adequately and will require a large
cohort study to conﬁrm these ﬁndings. It is important to
note, however, that south Asians had a higher baseline
eGFR, and this could be explained, in part, by ethnic
differences in referral patterns to our centre. Primary
care physicians may be more likely to refer south Asians
with early diabetic kidney disease compared to Whites,
reﬂecting concern that diabetic kidney disease in south
Asians is more difﬁcult to control and is associated with
a faster rate of decline.
Current national CKD guidelines do not include eth-
nicity as a risk factor for CKD.13 Therefore, the recom-
mendation for the management of CKD in general and
DCKD in particular for patients from different ethnic
minority groups is similar to that for the White popula-
tion. The results of this study suggest that there is no
need for a different set of guidelines for different ethnic
groups at present, and efforts should be directed at
determining the reasons behind suboptimal BP targets
in certain ethnic groups.
Strengths and weaknesses of the study
The strengths of this study include the large number of
cases, the completeness of ethnicity and clinical data
recording and the prolonged period of follow-up. The
communities from which these patients are drawn include
some of the most socially deprived and multiethnic popu-
lations in England; hence, our results will be of interest to
commissioning organisations throughout the UK.
Weaknesses include combining ethnic subgroups into
three broad categories, which may mask differences in
treatment or progression. We are also unable to identify
differences in referral thresholds and patterns by the GP
practices in the localities. Another perceived weakness
of the study could be combining diabetic patients with
types 1 and 2 for analysis. However, in a real-life setting,
only differences in patients with CKD with types 1 and 2
are stages at which patients are referred because of the
variable period of undiagnosed type 2 DM. However,
regardless of the type of diabetes and the stage of renal
involvement, achievement of SBP/DBP values of 130/
80 mm Hg or less and of HbA1c levels of 7.5% or less
are of paramount importance for the beneﬁcial effect
which optimal BP and metabolic control may have on all
the other macrovascular and microvascular chronic com-
plications of diabetes.14
Table 4 Ethnic differences in risk of death rate using Cox
regression
Ethnic group HR* 95% CI p Value
White (ref) 1 – –
Black 1.01 0.63 to 2.57 0.982
South Asian 1.17 0.68 to 2.32 0.718
*Adjusted for age and gender.
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CONCLUSION
This study demonstrates that there is no signiﬁcant inter-
action between ethnicity and the rate of progression of
CKD in patients with DM. Furthermore, the prevalence
of RRT, indicating ESKF, and mortality was also similar
between the three groups.
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